Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* • Healthy adults (18-40 yrs), toddlers (12-15 mo), full term infants (6-8 wks) and ≥ 3.5 kg~  * Able to provide informed consent (for themselves or child)~ * Willing to comply with study requirements and procedures.~ * Toddlers have completed their Gambian infant EPI schedule~ * Infants who have received the birth doses of BCG, HepB and OPV but who have not received any additional vaccines.~ * Infants and toddlers with a weight-to-height Z score of ≥ -2.~ * Subjects resident in the study area with no plans to travel outside the study area during the period of study participation.~Exclusion Criteria:~* Use of any investigational medicinal product within 90 days prior to randomization and throughout the study.~* Ingestion of herbal or other traditional local medication within 14 days of randomization.~* Adults and infants who have previously been vaccinated against S. pneumoniae.~* History of S. pneumoniae infection confirmed by culture from a normally sterile site.~* History of allergic disease or history of a serious reaction to any prior vaccination or known hypersensitivity to any component of the study vaccines.~* History of anaphylactic shock.~* Screening laboratory test or vital signs outside the normal range.~* HIV-positive or HbsAg- positive based on testing during screening.~* Acute illness (moderate or severe) and/or fever (axillary temperature of ≥ 38.0°C for adults or ≥ 37.5°C for toddlers and infants).~* Use of antibiotics within 5 days of randomization (excluding treatment for malaria).~* A positive test for malaria at time of screening, which remains positive post treatment when retested at time of randomization (Day 0).~* Administration of any non-study vaccine within 30 days prior to administration of study vaccine or planned vaccination during the course of study participation.~* Chronic administration of immunosuppressant or other immune modifying drugs prior to the administration of the study. The use of topical and inhaled glucocorticoids will be permitted.~* Administration of immunoglobulins and/or any blood products within the 6 months prior to administration of the study vaccine or during the study period.~* History of known disturbance of coagulation or blood disorder that could cause anemia or excess bleeding.~* Employee of, or direct descendant of any person employed by the Sponsor, the CRO, the PI, study site personnel, or site.~Adults only~* Recent history or signs of alcohol or substance abuse.~* History of major psychiatric disorder.~* Female adult subjects who are pregnant or breast-feeding. Infants/Toddlers only~* Family history of suspected primary immunodeficiency in first-degree relative.~* Had a sibling die suddenly and without apparent other cause or preceding illness in the first year of life.~* Evidence of a clinically significant congenital abnormality as judged by the PI.~* Evidence of fetal alcohol syndrome or maternal history of alcohol abuse during pregnancy.~* History of meningitis, seizures or any neurological disorder.~* Evidence of exposure to an HIV-positive individual through maternal fetal transmission, breast milk, or other bloodborne mechanisms

- Gender: ALL
- Minimum Age: 4 Weeks
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Adult SIILPCV10 (Type: EXPERIMENTAL): Single dose of SIILPCV10 on day 0
- Adult Pneumovax 23 (Type: ACTIVE_COMPARATOR): Single dose of Pneumovax 23 on day 0
- Toddler SIILPCV10 (Type: EXPERIMENTAL): Single dose of SIILPCV10 on day 0
- Toddler Prevenar 13 (Type: ACTIVE_COMPARATOR): Single dose of Prevenar 13 on day 0
- Infants SIIL PCV10 (Type: EXPERIMENTAL): A three-dose series of SIILPCV10 on day 0, day 28, and day 56
- Infants Prevenar 13 (Type: ACTIVE_COMPARATOR): A three-dose series of Prevenar 13 on day 0, day 28, and day 56
- Infant Booster Dose SIILPCV 10 (Type: EXPERIMENTAL): One dose of SIILPCV 10 at 9 months of age
- Infant Booster Dose Prevenar 13 (Type: ACTIVE_COMPARATOR): One dose of SIILPCV 10 at 9 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete